Genomic Health (GHDX) Tops Q4 EPS by 5c, Offers Guidance

Genomic Health (NASDAQ: GHDX) reported Q4 EPS of $0.04, 5 cents better than the analyst estimate of ($0.01). Revenue for the quarter came in at $82.7 million versus the consensus estimate of $84.08 million.

2017 Financial Guidance

"In 2017 at the mid-point of revenue guidance, we expect to deliver 11 percent revenue growth and positive net income for the full year, which requires operating leverage of more than 40 percent," said Brad Cole, chief operating officer and chief financial officer of Genomic Health. "We anticipate that expected reimbursement progress in the second half of the year will contribute to accelerated revenue growth."

The company is providing the following financial guidance for the full year ending December 31, 2017:

Total product revenue of between $355 to $370 million, representing growth of between 9 and 13 percent compared to 2016; and
Positive net income at mid-point of revenue guidance.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04